In RCC patients, especially those diagnosed with ccRCC and VHL disorders caused by familial mutations, disruption of signaling pathways inhibited by tyrosine kinase inhibitors and other related inhibitory drugs is most effective (Mickley et al., 2015). This evidence concerns the gene VHL and renal cell carcinoma.